Translate Bio to Participate in Upcoming Investor Conferences
03 sept. 2020 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Recent Progress
06 août 2020 16h14 HE
|
Translate Bio, Inc.
-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class vaccine...
Translate Bio Announces Closing of Expanded Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for All Infectious Diseases
20 juil. 2020 16h05 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Proposed Public Offering of Common Stock
24 juin 2020 16h18 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio to Present at Jefferies Virtual Healthcare Conference
28 mai 2020 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference
12 mai 2020 16h05 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
07 mai 2020 16h26 HE
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...
Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19
27 mars 2020 02h00 HE
|
Translate Bio, Inc.
The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development PARIS and LEXINGTON, Mass., March 27,...
Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
12 mars 2020 16h45 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
26 févr. 2020 07h30 HE
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...